We attended ISEV 2025, one of the world’s leading conferences focused on extracellular vesicles. It was an impressive event centered around groundbreaking science, new connections and a dynamic exchange of ideas.
We were particularly excited to see in vivo studies confirming the potential of exosomes — including plant-derived ones — as delivery vehicles for both intranasal and oral administration. This demonstrated ability to safely transport genetic constructs via non-invasive routes brings us significantly closer to the clinical use of gene therapy.
These findings resonate deeply with our mission at Vita Motus AG and further reinforce our belief in the transformative promise of exosome-based technologies. We are continuing to integrate these insights into our work and help drive the development of next-generation therapeutics.
